Every year around 500,000 people in Germany are diagnosed with cancer. New active ingredients based on so-called low molecules, i.e.
with a mass of less than 800 g/mol, are intended to offer new treatment options, especially for advanced cancers. Current research focuses on the development of substances that can be used in immunotherapy, as well as on small-molecule active ingredients. The targeted effect of the newly developed drugs should help reduce the side effects of cancer therapy.